TY - JOUR
T1 - Association of allergic diseases and epilepsy with risk of glioma, meningioma and acoustic neuroma
T2 - results from the INTERPHONE international case–control study
AU - Schlehofer, Brigitte
AU - Blettner, Maria
AU - Moissonnier, Monika
AU - Deltour, Isabelle
AU - Giles, Graham G.
AU - Armstrong, Bruce
AU - Siemiatycki, Jack
AU - Parent, Marie Elise
AU - Krewski, Daniel
AU - Johansen, Christoffer
AU - Auvinen, Anssi
AU - Lahkola, Anna
AU - Hours, Martine
AU - Berg-Beckhoff, Gabriele
AU - Sadetzki, Siegal
AU - Lagorio, Susanna
AU - Takebayashi, Toru
AU - Yamaguchi, Naohito
AU - Woodward, Alistair
AU - Cook, Angus
AU - Tynes, Tore
AU - Klaboe, Lars
AU - Feychting, Maria
AU - Feltbower, Richard
AU - Swerdlow, Anthony
AU - Schoemaker, Minouk
AU - Cardis, Elisabeth
AU - Schüz, Joachim
N1 - Funding Information:
The authors like to thank Mr Klaus Schlaefer (German INTERPHONE team) for his contribution to this work and to INTERPHONE Germany in general, who sadly passed away before the end of this project. The authors are grateful to Lesley Richardson (Montreal, Canada – formerly at IARC) for her major role in the coordination of the study; Emilie Combalot and Helene Tardy for their skillful data management at the coordination centre; Dr Baruch Modan (Israel – deceased) for his assistance and enthusiasm in the design and setting up of this study; James Doughty (UK North), who performed miracles implementing the CAPI in several languages and several versions, assisted by Roger Parslow (UK North); Jan Ivar Martinsen for additional programming work; Liz Findlay (UK North) who contributed a great deal to the development of materials and training of interviewers; the research assistants and interviewers in the different study centres who ensured that the study was carried out with care and consideration for the participants; the clinical practitioners, particularly neurosurgeons and ear, nose and throat surgeons, who permitted and facilitated our approaches to their patients; and the participants who gave so generously of their time. The Australian team would like to acknowledge the overall support given to study design and implementation by Associate Prof. Michael Besser and Prof. Andrew Kaye; the special support Associate Prof. Besser and Dr Paul Fagan gave to this study of acoustic neuroma.
Publisher Copyright:
© 2022, Springer Nature B.V.
PY - 2022/5
Y1 - 2022/5
N2 - We investigated the association of allergic diseases and epilepsy with risk of brain tumours, in Interphone, a 13-country case–control study. Data were obtained from 2693 glioma cases, 2396 meningioma cases, and 1102 acoustic neuroma cases and their 6321 controls. Conditional logistic regression models were used to estimate pooled odds ratios (ORs) and their respective 95% confidence intervals (CIs), adjusted for education and time at interview. Reduced ORs were observed for glioma in relation to physician-diagnosed asthma (OR = 0.73; CI 0.58–0.92), hay fever (OR 0.72; CI 0.61–0.86), and eczema (OR 0.78, CI 0.64–0.94), but not for meningioma or acoustic neuroma. Previous diagnosis of epilepsy was associated with an increased OR for glioma (2.94; CI 1.87–4.63) and for meningioma (2.12; CI 1.27–3.56), but not for acoustic neuroma. This large-scale case–control study adds to the growing evidence that people with allergies have a lower risk of developing glioma, but not meningioma or acoustic neuroma. It also supports clinical observations of epilepsy prior to the diagnosis of glioma and meningioma.
AB - We investigated the association of allergic diseases and epilepsy with risk of brain tumours, in Interphone, a 13-country case–control study. Data were obtained from 2693 glioma cases, 2396 meningioma cases, and 1102 acoustic neuroma cases and their 6321 controls. Conditional logistic regression models were used to estimate pooled odds ratios (ORs) and their respective 95% confidence intervals (CIs), adjusted for education and time at interview. Reduced ORs were observed for glioma in relation to physician-diagnosed asthma (OR = 0.73; CI 0.58–0.92), hay fever (OR 0.72; CI 0.61–0.86), and eczema (OR 0.78, CI 0.64–0.94), but not for meningioma or acoustic neuroma. Previous diagnosis of epilepsy was associated with an increased OR for glioma (2.94; CI 1.87–4.63) and for meningioma (2.12; CI 1.27–3.56), but not for acoustic neuroma. This large-scale case–control study adds to the growing evidence that people with allergies have a lower risk of developing glioma, but not meningioma or acoustic neuroma. It also supports clinical observations of epilepsy prior to the diagnosis of glioma and meningioma.
KW - Allergies
KW - Brain tumours
KW - Epilepsy
KW - Multicenter case–control study
UR - http://www.scopus.com/inward/record.url?scp=85124230439&partnerID=8YFLogxK
U2 - 10.1007/s10654-022-00843-y
DO - 10.1007/s10654-022-00843-y
M3 - Article
C2 - 35118581
AN - SCOPUS:85124230439
SN - 0393-2990
VL - 37
SP - 503
EP - 512
JO - European Journal of Epidemiology
JF - European Journal of Epidemiology
IS - 5
ER -